Well-known member
And Swiss citizen I thought. Swiss EPP patients have obtained access to Scenesse since 2010. They have the best view on long term protection, efficacy, safety and general health benefits involved. Does clinuvel plan a survey on this? This could have mind boggling outcomes. Maybe more interesting than the XP trial especially from longitudinal perspective.


New member
So guys, when do you think will the real short squeeze begin? ;)🤑 things are getting bad and expensive for these shorties. They will soon be forced to cover by their lenders…

CUV Quote (Yesterday's close)

Time: 4:10PM AEDT
Price: 39.19
Volume: 69444